Skip to main content
Premium Trial:

Request an Annual Quote

Oncore Pharma Signs European Marketing Deal for Colorectal Cancer Test

NEW YORK — Oncore Pharma said today that it has partnered with Dutch medical testing firm BodyCheck to commercialize the ColonSentry colorectal cancer test in Belgium, the Netherlands, and Luxembourg in a deal valued at $61.8 million. 

ColonSentry is a blood-based test designed to evaluate the expression of seven genes in order to determine an individual's current risk for colorectal cancer relative to an average risk population. Cambridge, Massachusetts-based Oncore acquired the rights to commercialize the test in all countries outside the US and Canada from StageZero Life Sciences — formerly GeneNews — earlier this year.

According to Oncore, BodyCheck will launch the test in the three countries during the first six months of the deal. BodyCheck has also agreed to sell a minimum of 275,000 tests, which will be processed by StageZero at its Virginia-based lab, translating to roughly $61.8 million in revenues to Oncore.

Additional terms were not disclosed.

"This is an important initial start for us in Europe," Oncore President and CEO Martin Verronneau said in a statement. "The signature of this first agreement less than four months after our partnership with StageZero Life Sciences is putting us ahead of schedule in creating sustainable value for our shareholders."

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.